SDTM IG - Trial Design - Elements, Cycles, and Transitions Question 1 of 22
An oncology protocol repeats chemotherapy cycles until disease progression. The protocol does not specify a fixed maximum number of cycles, but in the completed trial the maximum observed was four cycles. How should TA handle the repeating design for submission?